PRAN - Prana Biotechnology Limited

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
2.124
+0.134 (+6.73%)
At close: 3:59PM EDT

2.220 +0.10 (4.52%)
After hours: 6:39PM EDT

Stock chart is not supported by your current browser
Previous Close1.990
Open1.950
Bid2.080 x 3000
Ask2.220 x 1400
Day's Range1.910 - 2.124
52 Week Range1.750 - 3.790
Volume129,282
Avg. Volume69,893
Market Cap17.989M
Beta0.34
PE Ratio (TTM)N/A
EPS (TTM)-0.660
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Trade prices are not sourced from all markets
  • Business Wire2 months ago

    PBT434 Data to be Presented at the International Congress of Parkinson’s Disease and Movement Disorders

    Prana Biotechnology Ltd (ASX PBT: NASDAQ PRAN) has today announced it will be presenting further pre-clinical evidence for PBT434 at the International Congress of Parkinson’s Disease and Movement Disorders® to be held in Hong Kong from October 5-9, 2018. The data to be presented will include new in-vivo evidence of the efficacy of PBT434 to prevent neuron loss and improve function in an animal model of Multiple system atrophy (MSA), an important cause of atypical Parkinsonism. MSA is a rapidly progressive and devastating neurological disease with no established treatments and is one of the target indications for PBT434.

  • Business Wire3 months ago

    First Volunteers Dosed in Phase I Clinical Trial of PBT434, Prana’s Lead Therapy for Parkinsonian Diseases

    Prana Biotechnology Ltd (ASX PBT: NASDAQ PRAN) is pleased to announce the first cohort of volunteers in its Phase I clinical trial have been administered PBT434, an experimental drug under investigation for the treatment of Parkinsonian diseases. The trial conducted in Melbourne, Australia is recruiting and dosing healthy adult and elderly volunteers, to ascertain the optimal drug dose.

  • Business Wire3 months ago

    Prana to Commence Phase 1 Clinical Trial of PBT434 for Treatment of Parkinsonian Diseases

    Prana Biotechnology Ltd is pleased to announce it has received ethics committee approval and has commenced recruitment for its Phase I Clinical trial evaluating the safety, tolerability and pharmacokinetics of the Company’s lead drug candidate, PBT434, in healthy volunteers.

  • ACCESSWIRE11 months ago

    Today's Research Reports on Trending Tickers: Agenus and Prana Biotechnology

    NEW YORK, NY / ACCESSWIRE / October 20, 2017 / The Dow Jones and S&P 500 rallied late to close in the green Thursday, which was the 30th anniversary of the 1987 Black Monday stock market crash. The Dow ...